Pfizer's Xalkori gets a lung cancer indication in EU and Lilly's Portrazza gets one from FDA; Pfizer's Lyrica comes up short in post-traumatic neuropathic pain trial;

@FiercePharma: Scientists roll out innovative health-tracking device for guide dogs. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI: warning letter says Dr Reddy's hid existence of QC testing lab where retesting was done. Report | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Trump, Clinton lash out at Pfizer over Allergan deal agreement. Article | Follow @CarlyHFierce

> Pfizer ($PFE) has won a label expansion in the EU for Xalkori as a first-line treatment for adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). Release

> Pfizer's blockbuster pain drug, Lyrica failed to show benefit in patients suffering from a type of post-traumatic neuropathic pain, for which there is no approved drug in the U.S. Story

> Daiichi Sankyo is teaming up with Sanofi's ($SNY) Japanese unit to launch Squarekids, a DPT-polio vaccine, in Japan. Story

> The FDA has approved Eli Lilly's ($LLY) Portrazza to treat advanced squamous non-small cell lung cancer. Release

> Mylan has launched Clozapine orally disintegrating tablets--a generic of Jazz Pharmaceutical's ($JAZZ) FazaClo--in the U.S. Release

Medical Device News

@FierceMedDev: Cigna rolls out new coverage policy for whole exome sequencing. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI from FierceDrugDelivery: Physicians call for novel abuse-deterrent opioid agonist/antagonist formulations in survey. Story | Follow @VarunSaxena2

@EmilyWFierce: Scientists roll out innovative health-tracking device for guide dogs. FierceAnimalHealth story | Follow @EmilyWFierce

> Entellus wins FDA clearance for its endoscope to treat blocked sinus passages. More

> Alphabet gives startups a lesson in financial management. Article

Biotech News

@FierceBiotech: FierceBiotech Radio on the ins and outs of 'Pfizergan' and whatever it is Martin Shkreli's doing. More | Follow @FierceBiotech

@JohnCFierce: Any journos who would like to attend our breakfast event on Big Data? Drop me a line @ [email protected] More info | Follow @JohnCFierce

> Novo Nordisk taps Ablynx in a $400M deal. Item

> Allergan scoops up some CNS drugs as its $160B Pfizer merger pends. More

Pharma Marketing News

> Meda breaks down asthma with Medikidz comic book series for children. Report

> Kantar Media survey: Not all docs hate all ads. Article

> Turing sidesteps list-price discount on jacked-up therapy Daraprim. Item

> Purple haze: Dr. Reddy's strikes back at AstraZeneca in Nexium court battle. Story

> If TV's everywhere, then where does pharma need to be? More

Biotech Research News

> Sanford Burnham team sees promise in new melanoma drug. More

> Fruit flies may provide a biomarker for early-onset Parkinson's. Item

> U.K. investigators publish small, promising study of Victoza for NASH. Report

> Arno's HDAC inhibitor looks promising in preclinical cachexia study as cash runs low. Story

> Mount Sinai team maps a key combo role for new checkpoint drugs. Article

Vaccines News

> Daiichi Sankyo, Sanofi to launch DPT-polio vaccine in Japan. News

> Vaxart's oral RSV candidate protects in preclinical challenge. Report

> SUNY Upstate Medical University, U.S. Army start $12M partnership toward dengue vaccine. More

> FDA expands indication of Emergent BioSolutions anthrax vaccine. Article

> Celldex's brain cancer vaccine Rintega shows survival advantage at 2-year mark. Story

And Finally... The FDA has expanded the indication of Emergent BioSolutions ($EBS) anthrax vaccine, BioThrax, for use in adults aged 18 to 65 in conjunction with antibiotic treatment, following confirmed or suspected exposure. Story

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.